Mapping an antibody’s epitope, where it binds a target, can now be done in three dimensions, which optimizes the selection of application-specific antibodies.

over antibody phage display technology. Nevertheless, despite scientific and legal issues, the biopharmaceutical industry has embraced the notion that the more “humanlike” the mAb, the greater ...

announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology. IONTAS’ platform allows for the construction of large ...

Examples of antibody sequences accepted: variable region sequenced from hybridoma, hits (Fab or scFv) selected from display library based method, sequences from single B cell and/or repertoire ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

To identify a candidate therapeutic antibody, researchers generally screen and test thousands of antibodies against an antigen target, looking for the "needle in the haystack" that binds to and ...

Hemagglutination would be positive for maternal cells that have been bound with anti-D Also known as the "antibody screen" that is drawn before the administration of RhIG to RhD-negative women.

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, today announces the launch of PRE-CISE, a Eurostars-funded research collaboration with Danish PreTT and TetraKit ...

including peptide scanning and microbial display, aiming to precisely map the antibody binding site (epitope) on a target protein. This mapping is then visualized in an interactive 3D view ...